Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is well-positioned for future growth with its strong and diverse product portfolio focused on aortic solutions, expansion into key international markets, and consistent revenue and margin growth. While the company does face some risks, such as non-North American revenue and regulatory challenges, its strong financials and positive outlook make it a favorable investment opportunity for analysts. Its recent 1Q26 results showed a slight beat in top-line revenue but a lowered full-year guidance due to temporary challenges in international stent graft sales and slower initial stocking orders for a new product. However, these issues are expected to improve throughout the year and do not affect the overall long-term potential of the company.

Bears say

Artivion is facing significant challenges in the near future, with guidance resets and potential disruptions due to the delayed launch of the NEXUS product. While it is positioned well for long-term growth and has a strong base business, the recent financials show underwhelming performance with a revenue beat but a missed consensus on EBITDA and lowered guidance for 2026. The company is also facing significant debt and earnout payments for its recently acquired products, which will likely impact its ability to generate free cash flow in the short term. Additionally, management has identified barriers to adoption for its products, which may delay the commercial success of its new launches.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.